AB103261

Anti-Cisplatin modified DNA antibody [CP9/19]

Name: Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261) | Abcam
Brand: Abcam Limited
SKU: AB103261
Price: 340 USD
Availability: InStock
Rating: 4 (4 reviews)

(4 Reviews)

(51 Publications)

Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261) is a rat monoclonal antibody detecting Cisplatin modified DNA in ELISA.

- Over 40 publications
- Trusted since 2010

Key facts

Host species

Rat

Clonality

Monoclonal

Clone number

CP9/19

Isotype

IgG2a

Carrier free

Applications

ELISA

applications

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Nucleic Acid": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>" } } }

style

left-column

Product details

What is this antibody validated in?
Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261) is a rat monoclonal antibody and is validated for use in ELISA. Trusted by the scientific community
Anti-Cisplatin modified DNA [CP9/19] (ab103261) was first used in a scientific publication in 2010 and has been cited over 40 times in peer-reviewed journals.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A/G

Storage buffer

Preservative: 0.02% Sodium azide Constituents: PBS

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

See full target information Cisplatin modified DNA

style

left-column

Publications (51)

Recent publications for all applications. Explore the full list and refine your search

Nucleic acids research 53: PubMed40433977

2025

3D genome organization shapes DNA damage susceptibility to platinum-based drugs.

Applications

Unspecified application

Species

Unspecified reactive species

Ye Wang,Asli Yildirim,Lorenzo Boninsegna,Valentina Christian,Sung-Hae L Kang,Xianghong Jasmine Zhou,Frank Alber

Nature communications 15:7089 PubMed39154022

2024

Coordination of transcription-coupled repair and repair-independent release of lesion-stalled RNA polymerase II.

Applications

Unspecified application

Species

Unspecified reactive species

Yongchang Zhu,Xiping Zhang,Meng Gao,Yanchao Huang,Yuanqing Tan,Avital Parnas,Sizhong Wu,Delin Zhan,Sheera Adar,Jinchuan Hu

Nature communications 15:5237 PubMed38898005

2024

Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between ovarian cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Victoria O Shender,Ksenia S Anufrieva,Polina V Shnaider,Georgij P Arapidi,Marat S Pavlyukov,Olga M Ivanova,Irina K Malyants,Grigory A Stepanov,Evgenii Zhuravlev,Rustam H Ziganshin,Ivan O Butenko,Olga N Bukato,Ksenia M Klimina,Vladimir A Veselovsky,Tatiana V Grigorieva,Sergey Y Malanin,Olga I Aleshikova,Andrey V Slonov,Nataliya A Babaeva,Lev A Ashrafyan,Elena Khomyakova,Evgeniy G Evtushenko,Maria M Lukina,Zixiang Wang,Artemiy S Silantiev,Anna A Nushtaeva,Daria D Kharlampieva,Vassili N Lazarev,Arseniy I Lashkin,Lorine K Arzumanyan,Irina Yu Petrushanko,Alexander A Makarov,Olga S Lebedeva,Alexandra N Bogomazova,Maria A Lagarkova,Vadim M Govorun

Molecules (Basel, Switzerland) 29: PubMed38893499

2024

Trichostatin A Promotes Cytotoxicity of Cisplatin, as Evidenced by Enhanced Apoptosis/Cell Death Markers.

Applications

Unspecified application

Species

Unspecified reactive species

Yang Zhou,Qun Luo,Fangang Zeng,Xingkai Liu,Juanjuan Han,Liangzhen Gu,Xiao Tian,Yanyan Zhang,Yao Zhao,Fuyi Wang

Molecular oncology 18:1866-1884 PubMed38750006

2024

Glutathione S-transferase omega class 1 (GSTO1)-associated large extracellular vesicles are involved in tumor-associated macrophage-mediated cisplatin resistance in bladder cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yi-Cheng Pan,Pei-Yi Chu,Ching-Chan Lin,Ching-Yun Hsieh,Wei-Yu Hsu,Lie-Fen Shyur,Juan-Cheng Yang,Wei-Chao Chang,Yang-Chang Wu

NAR cancer 5:zcad057 PubMed38058548

2023

Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy.

Applications

Unspecified application

Species

Unspecified reactive species

Jana Slyskova,Alba Muniesa-Vargas,Israel Tojal da Silva,Rodrigo Drummond,Jiyeong Park,David Häckes,Isabella Poetsch,Cristina Ribeiro-Silva,Amandine Moretton,Petra Heffeter,Orlando D Schärer,Wim Vermeulen,Hannes Lans,Joanna I Loizou

Nucleic acids research 51:e32 PubMed36715337

2023

Genome-wide mapping of protein-DNA damage interaction by PADD-seq.

Applications

Unspecified application

Species

Unspecified reactive species

Yongchang Zhu,Yuanqing Tan,Lin Li,Yuening Xiang,Yanchao Huang,Xiping Zhang,Jiayong Yin,Jie Li,Fei Lan,Maoxiang Qian,Jinchuan Hu

British journal of cancer 127:1340-1351 PubMed35778553

2022

Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hugh A Nicholson,Lynne Sawers,Rosemary G Clarke,Kevin J Hiom,Michelle J Ferguson,Gillian Smith

Cell death & disease 13:350 PubMed35428778

2022

Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

Trace M Jones,Claudia M Espitia,Aikseng Ooi,Julie E Bauman,Jennifer S Carew,Steffan T Nawrocki

Cell death & disease 13:241 PubMed35296653

2022

Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca release in cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Vidhya Tangeda,Yu Kang Lo,Ananth Ponneri Babuharisankar,Han-Yu Chou,Cheng-Liang Kuo,Yung-Hsi Kao,Alan Yueh-Luen Lee,Jang-Yang Chang

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Cisplatin modified DNA antibody [CP9/19]

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Applications

Complementary Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Product protocols

Target data

Publications (51)

Product promise